Results ART and DHA had the most potent activity in a panel of AML cell lines, with selectivity toward samples harboring MLL rearrangements and FLT3-ITD mutations. Combination of ART or DHA was synergistic with cytarabine. Single-dose ART (120 mg/kg) produced human equivalent exposures, but multiple dose daily administration required for in vivo efficacy was not tolerated. Combination treatment produced initial regression, but did not prolong survival in vivo. Conclusions The pharmacology of artemisinins is problematic and should be considered in designing AML treatment strategies with currently available agents. Artemisinins with improved pharmacokinetic properties may offer therapeutic benefit in combination with conventional therapeutic strategies in AML.
Introduction
Dramatic improvements in survival have been achieved for children and adolescents with acute myeloid leukemia (AML), with the 5-year survival rate increasing from less than 20 % to more than 70 % [1] . Survival rates in adults are not as favorable, with more than half of young adult patients and about 90 % of older patients still succumbing to their disease [2] . Given that significant improvements in long-term outcome are not expected with conventional therapy alone, new therapeutic strategies that can be rapidly advanced to the clinical setting are urgently needed for the treatment of AML.
Artemisinin is a natural product from the herb Artemisia annua L. Multiple derivatives have been developed with improved pharmacological features, which are rapidly converted to the active metabolite dihydroartemisinin (DHA) [3] . Since artemisinins have an established safety record for the treatment of malaria in millions of patients, including children, there is an increased interest in the potential repurposing of this class of compounds for multiple indications, such as cancer [4, 5] . In leukemia, artemisinins have been shown to induce cell cycle arrest [6] , activate apoptosis through ROS dependent and independent mechanisms [7, 8] , and cause lysosomal disruption [9] . Recently, investigators performed a drug screen using primary patient samples and found one antimalarial compound, quinacrine, with activity in three subtypes of AML and low activity in normal peripheral blood mononuclear cells [10] ; however, the antileukemic activity was not confirmed using in vivo models. In a recent report, Sukhai et al. [9] demonstrated the antimalarial agent mefloquine could induce tumor regression in a subcutaneous model of AML and reduced engraftment of primary AML samples. To our knowledge, no studies have demonstrated a prolonged survival advantage after treatment with artemisinins or similar agents using in vivo models of AML.
In this report, we conducted a high-throughput screen (HTS) to evaluate the antileukemic activity of antimalarial compounds against a panel of AML cell lines, including five cells lines that were derived from children; artesunate (ART) and DHA were found to have the most potent activity. In vitro and in vivo studies demonstrated a selectivity for samples harboring mixed linage leukemia (MLL) rearrangements (including t(6; 11); t(4; 11); t(9; 11)) and fmslike kinase 3 internal tandem duplications (FLT3-ITD). Furthermore, we determined that combining either ART or DHA with the AML standard of care chemotherapy, cytarabine (Ara-C), potentiated antileukemic activity in cell lines and primary patient blast samples. We performed ART and DHA pharmacokinetic studies in mice and identified an oral ART dose that produced human equivalent DHA exposure, albeit with a short half-life. Finally, we showed that ART produces initial regressions in several mouse xenograft models; ultimately, however, negligible survival benefit was observed with ART administered as a single agent or in combination with Ara-C. Taken together, these results support the continued effort to develop novel artemisinin compounds with improved clinical pharmacology properties and enhanced anticancer activity that will effectively combine with standard of care chemotherapy.
Materials and methods

Cell culture and reagents
Human AML cell lines HEL92.1.7, MV4-11, and U937 cells were obtained from American Type Culture Collection (Manassas, VA); ML-2, M07e, and MOLM-13 cells were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany); CHRF288-11 cells were a kind gift from Dr. Tanja Gruber [St. Jude Children's Research Hospital (SJCRH)]; CMK and CMS cells were a kind gift from Drs. Jeffrey Taub (Karmanos Cancer Center); mFLT3 cells were a kind gift from Dr. Timothy Pardee (Wake Forest University); MOLM-13-RES cells were generated as previously described [11] . Cells were cultured in RPMI1640 media (Life Technologies, Grand Island, NY) supplemented with 10 % fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) at 37 °C in a humidified incubator with 5 % CO 2 . M07e cells were supplemented with 10 ng/mL interleukin-3 (Sigma-Aldrich, St Louis, MO). Primary AML blasts from eight patients with FLT3-ITD (N = 4) or MLL-rearranged leukemia (t(6; 11)) (N = 4) enrolled in the AML08 clinical trial were obtained from SJCRH Tissue Resources, following institutional guidelines. Mesenchymal stem cells (MSC) were cultured and maintained in RPMI1640 with 10 % FBS and 1 µM hydrocortisone (complete MSC media) (Sigma-Aldrich).
For in vitro studies, ART, DHA, and Ara-C were purchased from Sigma-Aldrich; ART and DHA were prepared in DMSO, and Ara-C was prepared in phosphate-buffered saline (PBS).
High-throughput screen
Briefly, for primary screening, cells were seeded in 25 µL culture medium in each well of 384-well plates (Corning, Tewksbury, MA) using an automated plate filler (Wellmate, ThermoFisher Scientific, Waltham, MA). After 24 h, 50 nL of solution containing a panel of antimalarial compounds (N = 9) was pin transferred into 384-well plates resulting in approximately 10 µM final drug concentration. Each plate included DMSO only negative controls and cyclohexamide single point (0.5 µM) and dose-response (0.01 nM-0.5 µM) positive controls. Cell viability was determined using Cell Titer Glo (Promega, Madison, WI) and an automated Envision plate reader (Perkin Elmer, Waltham, MA) after a 72 h incubation. Luminescence data were normalized by log 10 transformation and the percentage inhibition = 100 × (sample result − negative control mean)/(positive control mean − negative control mean) calculated. Secondary screens were conducted in a similar manner; a limited number of compounds (N = 5) were applied in serial dilution (0.5 nM-10uM final concentration) and repeated in triplicate. All data processing, quality control, and visualization were performed using custom programs written in the Pipeline Pilot platform (Accelrys, v.7.0.1, San Diego, CA) and the R program as previously described [12] . Plotly (Plotly, Inc, Montreal, Quebec) was used to generate a heatmap.
Cell viability assays
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich) in a low-throughput manner. Cell lines were seeded in 96-well plates and treated with increasing concentrations of ART (0.08-100 µM) or DHA (0.08-100 µM) for 72 h. Two to three independent experiments (12-18 total replicates per concentration) were performed.
For evaluation of 72 h continuous simultaneous combination drug treatment, cells (CMS, ML-2, MOLM-13, MV4-11, U937) were treated with ART or DHA and Ara-C. We also evaluated sequential combination; cells (CMS, MV4-11, U937) received 24 h pre-treatment with Ara-C followed by 48 h ART or DHA treatment (pre-Ara-C). Alternatively, cells (CMS, MV4-11, U937) received 24 h pre-treatment with ART or DHA followed by 48 h Ara-C treatment (pre-ART or pre-DHA). For sequential combination treatment, cells were seeded in a 96-well multi-screen filter plate (Millipore, Danvers, MA); prior to the 48 h treatment, cells were washed twice with 200 µL culture medium. Two independent experiments (nine total replicates per concentration) were performed. All combination experiments were performed using a fixed concentration ratio of drugs.
At 68 h after treatment, 10 µL of MTT reagent (5 mg/ mL MTT in PBS) was added to each well and plates were incubated at 37 °C with 5 % CO 2 for 4 h; formazan crystals were solubilized with 100 µL of acidified isopropanol (Sigma-Aldrich). The absorbance was measured using a Synergy H4 (Biotek Instruments, Inc., Winooski, VT). The half maximal inhibitory concentration (IC 50 ) was evaluated by nonlinear regression analysis in the software program GraphPad Prism version 5.04 (GraphPad Software, La Jolla, CA). The median effect approach to evaluate whether the combinations demonstrated synergistic, additive, or antagonistic effects was implemented, according to Chou and Talalay [13] using the computer software CalcuSyn (version 2.1; Biosoft, Cambridge, UK). Combination index (CI) values were assessed at the 50, 75, and 90 % effective dose (ED) corresponding to ED 50 , ED 75 , and ED 90 , and R 2 values were used to assess overall goodness of fit (all R 2 values were >0.90). CI value less than 0.9, 0.9-1.1, and more than 1.1 demonstrated synergistic, additive, and antagonistic effects, respectively.
Cytotoxicity and caspase assays
Cell toxicity and caspase activity were detected using CellTox Green assay kit (Promega) and Caspase-Glo assay kit (Promega), respectively. MV4-11 and ML-2 cells were prepared at a density of 200,000 cells/mL, and CellTox Green reagent was added at 10 µL per 5 mL of cell suspension.
Cells were seeded in black opaque 96-well plates and treated with single-agent ART or DHA (MV4-11: 0.03-10 µM; ML-2: 0.15-5 µM). Luminescence was measured at 0, 6, 24, and 48 h. For detection of caspase activity, MV4-11 cells were treated with single-agent ART or DHA (0.03-10 µM) and caspase activation was measured at 24 h. Two independent experiments (six total replicates per concentration) were performed.
ROS detection
ML-2, MOLM-13, or MV4-11 cells were seeded in black opaque 96-well plate at a density of 100,000 cells/well and treated with ART or DHA at 1 and 10 µM. At 24 h, 100 µL of 20 mM dihydroethidium (Sigma-Aldrich) was added to each well and incubated at 37 °C for 30 min in the dark. Cells were collected and washed twice with PBS; then, fluorescence was detected. Three independent experiments (12 total replicates per concentration) were performed.
Lysosomal integrity assay
MV4-11, MOLM-13, and ML-2 were seeded in 24-well plates at a density of 500,000 cells/well and were treated with 5 µM of ART or DHA. At 16 or 24 h, 100 µL of LysoTracker Red (Life Technologies) was added to each well and cells were incubated at 37 °C for 30 min. Subsequently, cells were centrifuged at 300×g for 5 min, supernatant was removed, and cell pellets were re-suspended in fresh media. Samples were filtered through a 40-µM nylon mesh and immediately analyzed by flow cytometry. Samples were assayed using BD LSR II or LSR Fortessa (BD Bioscience, San Jose, CA); data were acquired and analyzed using Diva software (BD Bioscience).
Ex vivo drug treatments with primary AML blast samples
Bone marrow MSCs were plated in 96-well plates at a density of 10,000 cells/well in complete MSC media. After
Artesunate (ART) and dihydroartemisinin (DHA) pharmacokinetics
NOD-SCID-IL2R ɣ null (NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME) and maintained under specific pathogen-free conditions in the SJCRH Animal Resource Center; all mouse experiments were approved by the SJCRH Animal Care and Use Committee. Pharmacokinetic studies were performed using 8-to 12-week-old female mice. ART 60 or 120 mg/kg was formulated in sodium bicarbonate (5 %, pH 8.9) and administered by oral gavage to five mice at each dose. Serial blood samples were obtained from individual mice at 5, 15, and 30 min from the submandibular vein using a lancet and at 1 and 2 h from the retro-orbital venous plexus using a heparinized capillary tube (ThermoFisher Scientific). A final blood draw was obtained at 3 h by a cardiac puncture. All blood samples were centrifuged at 3000×g for 5 min; then, plasma was separated and stored at −80 °C until analysis.
ART and DHA plasma concentrations were measured using a validated LC-MS/MS method [14] with modifications described in Supplementary Information. For plasma sample processing, 10 µl of PBS (0.5 M, pH 7.4) solution was added to 10 µL of sample. 50 µL of extraction solvent (250 ng/ml ART_d 4 and DHA_d 3 in acetonitrile) was pipetted into the sample solution. The sample was vortex-mixed for 30 s and centrifuged for 8 min at 10,000 rpm. 2 µl of supernatant was injected into the LC-MS/MS system for analysis. Pharmacokinetic parameters were calculated using noncompartmental methods in WinNonlin 6.2 software (Pharsight, St. Louis, MO). All data are presented as the mean and standard deviation (SD).
In vivo xenograft mouse models
For efficacy studies, NSG mice were purchased from Jackson Laboratory and maintained under specific pathogenfree conditions in the SJCRH Animal Resource Center; all mouse experiments were approved by the SJCRH Animal Care and Use Committee. Luciferase and YFP-positive MV4-11 cells (MV4-11-luc) were generated as previously described [11] .
Mice were injected intravenously via tail vein with 5 × 10 6 luciferase and YFP-positive MV4-11 (MV4-11-luc) cells as previously described [11] . Cell engraftment was monitored by noninvasive imaging performed once weekly starting on day 12 after injection. The luciferase substrate d-luciferin firefly potassium salt (Caliper Life Sciences Inc., Hopkinton, MA, USA) was administered by intraperitoneal injection at a dose of 150 mg/kg. Mice were anesthetized by 1.5-2.5 % isoflurane (Baxter, Deerfield, IL, USA) inhalation; bioluminescence was determined 5 min later using a Xenogen IVIS-200 imaging system (Perkin Elmer) in the Small Animal Imaging Center at SJCRH. Total body bioluminescence was quantified for the body area that included each mouse in its entirety (Living Image 4.3.1, Perkin Elmer). The mice were observed daily and humanely euthanized when showing signs of progressive disease including, hind limb paralysis, weight loss more than 15 %, and lethargy.
To evaluate antileukemic activity, on day 12, groups of nine tumor-bearing mice were randomly assigned, based on imaging data, to receive vehicle, ART 120 mg/kg once daily for 5 days (Monday to Friday) (ART regimen 1), Ara-C 6.25 mg/kg once daily for 5 days, or the combination. ART was formulated in sodium bicarbonate (5 %, pH 8.9) and administered by oral gavage. Ara-C was prepared in PBS for intraperitoneal injection. Treatment started on day 17 when significant bone marrow engraftment was observed, as determined by imaging analysis, and treatment continued for 4 weeks until vehicle-treated mice succumbed to leukemia.
Antileukemic activity was also evaluated in ML-2 and MOLM-13 xenograft models. ML-2 and MOLM-13 cells were labeled with luciferase and YFP using a CL20-luc-YFP construct as previously described [11, 15] . For efficacy studies in the ML-2 model, mice were intravenously injected with 5 × 10 6 cells; mice were randomized on day 21 to treatment groups based on imaging analysis, and treatment with the following was started on day 24 when significant bone marrow engraftment was observed: ART 120 mg/kg twice daily for 5 days (Monday-Friday) during week 1 followed by 100 mg/kg twice daily for 5 days during week 2 (ART regimen 2) or ART 100 mg/kg twice daily for 10 consecutive days (ART regimen 3). The dose reduction in ART regimen 2 was required after 1 week of treatment due to toxicity manifested as weight loss. For efficacy studies in the MOLM-13 model, mice were intravenously injected with 1 × 10 6 cells; mice were randomized on day 9 to treatment groups based on imaging analysis, and treatment was started on day 10 when significant bone marrow engraftment was observed: ART 120 mg/kg once daily for 5 days (ART regimen 1) or 100 mg/kg twice daily for 9 consecutive days (ART regiment 3).
Statistical analysis
Prism software (GraphPad Software) was used for statistical analyses. Kaplan-Meier analysis of animal survival and data statistical significance was determined by log-rank test with a P value <0.05. All other statistical tests performed were two-sided t test; a P value <0.05 was considered statistically significant.
Results
High-throughput screen to determine antileukemic activity of antimalarial compounds
We selected a panel of AML cell lines (N = 10) representing subtypes and genetic lesions associated with high risk and poor prognosis to evaluate the antileukemic activity of antimalarial compounds (N = 9) using a HTS. The primary screen was conducted at a single concentration (10 µM), and percent inhibition was determined relative to the positive control. All compounds demonstrated activity (>50 % inhibition) in at least two cell lines and three compounds (primaquine, ART, DHA) had activity in all cell lines screened (Supplementary Figure S1A) . Activity was further assessed in a secondary screen performed in a dose-response manner Table S1 ).
Activity of artemisinins on viability, cytotoxicity, and caspase activation in AML cell lines
Subsequently, we validated the activity of ART and DHA on cell viability in six AML cell lines, which were included in the HTS, following 72 h exposure by MTT assay. ART and DHA inhibited cellular viability in a dose-dependent manner. ART appeared to be slightly more potent than DHA against all six cell lines with the IC 50 values ranging from 0.092 to 1.5 µM and 0.24-2.5 µM, respectively ( Fig. 1a ; Table 1 Fig. 1a; Table 1 ).
Next, we determined the effect of artemisinins on cytotoxicity and apoptosis in two of the most sensitive cell lines, MV4-11 (Fig. 1b, c) and ML-2 ( Supplementary Figure S2A ). ART and DHA induced cytotoxicity in MV4-11 cells in a dose-and time-dependent manner; induction was initially observed at 1 µM after 24 h of treatment, with further cytotoxicity observed at 48 h. Similarly, we observed induction of apoptosis in MV4-11 cells as indicated by caspase 3/7 activation at 24 h after the start of treatment in a dose-dependent manner. However, in ML-2 cells, 48 h of treatment was required to observe an induction of cytotoxicity.
Artemisinins induce ROS generation and lysosomal disruption in AML cell lines
ART and DHA have been shown to induce ROS-mediated apoptosis or autophagy in Molt-4 cells [16] , doxorubicinresistant T leukemia cells [7] , and the AML cell lines K562 [17] , TEX and OCI-AML2 [9] ; similarly, mefloquine has been reported to induce apoptosis in TEX cells as a result of both ROS generation and lysosomal disruption [9] . Therefore, we assessed whether 24 h treatment of AML cell lines (MV4-11, MOLM-13, or ML-2) with ART and DHA at 1 and 10 µM resulted in an increase in ROS production. We observed a significant increase in ROS production ranging 1.5-1.6-fold over control in MV4-11 cells (Fig. 1d) . In contrast, minimal to no increase in ROS production was observed in ML-2 or MOLM-13 cells ( Supplementary Figure S2B) . Next, we determined whether the activity of artemisinins was mediated by disruption of lysosomal integrity using LysoTracker. We found treatment of AML cell lines with 5 µM ART and DHA for 24 h resulted in lysosomal disruption, as indicated by an increase in the percent of cells positive for LysoTracker red. This observation was most notable in MV4-11 cells (10.5 and 15.7 %, respectively) (Fig. 1e) and MOLM-13 cells (13.2 and 13.6 %, respectively), whereas the effect in ML-2 cells was negligible (Supplementary Figure S2C) . These findings indicate the cytotoxic effects of artemisinins on AML cells may be due, in part, by triggering ROS leading to lysosomal disruption and ultimately induction of apoptosis. Previously, increased expression of lysosomal biogenesis genes was observed in adult primary AML blast samples compared to normal hematopoietic cells, rendering AML cells preferentially sensitive to lysosomal disruption and apoptosis following treatment with the antimalarial agent mefloquine [9] . Interestingly, expression of similar lysosomal biogenesis genes was found to be enriched in pediatric primary AML blast samples with MLL rearrangements (Supplementary Figure S3 ) [18] , suggesting that this subtype of AML may be more sensitive to agents that induce lysosomal disruption, consistent with our results in AML cell lines.
Artemisinins potentiate the activity of Ara-C in AML cell lines
We next sought to determine the combination effects of artemisinins with Ara-C, the most widely used chemotherapeutic agent for the treatment of AML, in a panel of cell lines with 72 h simultaneous exposure. We observed additive to synergistic effects (CI range 0.56-1.1) with the combination of ART and Ara-C when administered simultaneously. In contrast, the combination of DHA and Ara-C was additive to antagonistic (CI range 1.0-1.6) in all cell lines, except in MV4-11 cells, and at higher concentrations (ED75, ED90) in ML-2 cells where the combination effects were synergistic (CI range 0.75-0.87) (Fig. 2a) . A more synergistic interaction was observed when drugs were administered sequentially, pre-treatment with DHA followed by Ara-C (CI range 0.37-0.72) and pre-treatment with Ara-C followed by ART (CI range 0.49-0.9) (Fig. 2b, c) .
Activity of artemisinins in primary AML blast samples
Next, we determined the ART sensitivity of primary blast samples from MLL-positive patients and FLT3-ITD-positive patients in a cell viability assay. Primary patient samples were co-cultured with MSCs, which secrete multiple Fig. 1 Activity of artemisinins in AML cell lines. a AML cells were treated with DMSO and increasing concentrations of artesunate (ART) or dihydroartemisinin (DHA) for 72 h, and cell viability was measured by MTT assay. Data are reported as percent control and represent mean ± SD of 2-3 independent experiments (total of 12-18 replicates per concentration). MV4-11 cells were exposed to increasing concentrations of ART or DHA and b cytotoxicity was measured by CellTox Green assay at 6, 24, and 48 h and c apoptosis was measured by Caspase-Glo assay at 24 h. Data are reported as percent control and represent mean ± SD of 2-3 independent experiments (total of 3-6 replicates per concentration). d MV4-11 cells were treated with 1 or 10 µM ART or DHA, and ROS production was measured using dihydroethidium at 24 h. Data are reported as fold increase over control and represent mean ± SD of two independent experiments (total of 12 replicates per concentration). e MV4-11 cells were treated with 5 µM ART or DHA and assessed for lysosomal integrity at 24 h using LysoTracker. Data are representative of two independent experiments cytokines that mimic the bone marrow microenvironment; this system gives stromal support to the primary blast samples while challenging the drug treatment. Overall, ART produced modest inhibition in both MLL-positive patient samples (IC 50 range 3.2-46.7 µM) and FLT3-ITD-positive patient samples (IC 50 range 0.7-31.8 µM) ( Fig. 3a ; Table 1 ). We then evaluated the combination effects with simultaneous administration of ART and Ara-C in the primary patient blast samples. We observed the combination to be synergistic in three of the MLL-positive samples (patients 1, 2, and 4), whereas only two of the FLT3-ITDpositive samples (patients 6 and 7) demonstrated a synergistic interaction (Fig. 3b) .
Pharmacokinetics of artesunate and DHA in NOD-SCID-IL2Rγ null mice
Prior to testing the in vivo activity of ART, we first determined the pharmacokinetic properties of ART and DHA following oral administration of ART in mice. ART was administered at a dose of 60 and 120 mg/kg, and serial blood sampling was performed over a 3-h period. Concentration-time profiles and a summary of ART and DHA pharmacokinetic parameters are shown in Supplementary Figure S4 . At doses of 60 and 120 mg/kg, mean values for DHA maximum plasma concentration (C max ) were 936 and 3955 µg/mL, respectively, and area under the concentration-time curve from time zero to 2 h (AUC last ) was 382 and 1869 µg/L h, respectively. The DHA AUC achieved at ART 120 mg/kg given orally to mice is comparable to values achieved in adults following administration of oral ART at doses of 2-4 mg/kg [19] .
Activity of artesunate in xenograft models of AML
Given that artemisinins demonstrated in vitro activity in FLT3-ITD-positive AML cell lines and primary patient blast samples and synergy was observed in combination with Ara-C, we evaluated the in vivo antileukemic effects of ART alone and in combination with Ara-C using a MV-11 xenograft mouse model. Mice were treated with ART 120 mg/kg once daily for 5 days (Monday-Friday) (ART regimen 1), Ara-C 6.25 mg/kg once daily for 5 days, or the combination for 4 weeks. We observed a significantly lower mean radiance at day 33 in mice treated with the combination compared to those treated with vehicle (P < 0.05) or Ara-C alone (P < 0.01) (Fig. 4a,  b) . However, treatment with ART alone or in combination with Ara-C failed to provide a survival benefit; the median survivals were 42, 39, 42, and 43 days in mice treated with vehicle, ART, Ara-C, or the combination, respectively (Fig. 4c) . Subsequently, we evaluated ART efficacy in ML-2 and MOLM-13 xenograft models. Since our pharmacokinetic studies demonstrated that DHA has a short half-life (~30 min) after ART administration, we gave ART twice daily to determine whether increased daily exposure would increase efficacy. In the ML-2 xenograft, ART 120 mg/kg administered twice daily for 5 days was only tolerated for 1 week (based on significant weight loss) and the dose was then reduced to 100 mg/kg twice daily for 5 days during week 2 (ART regimen 2). We also evaluated the efficacy of ART 100 mg/kg twice daily given for 9-10 consecutive days (ART regimen 3). Significantly lower leukemic infiltration (mean radiance) was observed on days 21 and 28 (P < 0.01) with ART regimen 2 compared to mice treated with vehicle or ART regimen 3 (Fig. 5a ). In addition, a significant survival benefit (median survival, 35 days; P = 0.0009) was observed with ART regimen 2 compared to mice treated with vehicle (median survival, 31 days) or ART regimen 3 (Fig. 5c) . We then evaluated ART regimens 1 and 3 in the MOLM-13 xenograft model. Although a reduction in imaging was observed on day 9 with ART regimen 3 compared to mice treated with vehicle or ART regimen 1 (P < 0.01), no survival benefit was observed with a median survival of 17 days in all treatment groups (Fig. 5b, d ).
Discussion
We report the antileukemic activity of artemisinins in AML cell lines and primary AML patient blast samples. In a HTS, multiple artemisinin derivatives and similar antimalarial agents demonstrated activity in a panel of AML cell lines representing high-risk groups associated with poor outcome. Since our secondary dose-response screen revealed ART and DHA to have the greatest activity, these compounds were selected for further evaluation , cytarabine (Ara-C), or combination (ART or DHA and Ara-C) at a fixed concentration ratio for 72 h, and cell viability was measured by MTT assay. Multiple combination strategies were evaluated a simultaneous treatment (simultaneous Ara-C + ART or simultaneous Ara-C + DHA); b preartemisinin treatment for 24 h followed by Ara-C (Pre-ART + Ara-C or Pre-DHA + Ara-C) for 48 h; and c pre-Ara-C treatment for 24 h followed by ART or DHA (Pre-Ara-C + ART or Pre-Ara-C + ART) for 48 h. To assess the drug combination effect, combination index (CI) values were generated using Calcusyn. CI value >1.0, antagonistic; CI value =1.0, additive; CI value <1.0, synergistic. Data are reported as percent control and represent the mean ± SD of 2-3 independent experiments (total of 12-18 replicates) in vitro. Low-throughput cell viability assays confirmed the observed activity in the HTS; we found the MV4-11 cell line, which harbors an MLL rearrangement and FLT3-ITD, to be the most sensitive to ART and DHA. Mechanistic studies in the MV4-11 cell line confirmed significant ROS production following treatment with artemisinins, which was accompanied by caspase activation and decreased lysosomal integrity. These finding are consistent with previous reports evaluating underlying mechanisms of artemisinin anticancer properties [9, 20, 21] . In contrast, we did not observe alterations in ROS production or changes in lysosomal integrity in the ML-2 cell line, suggesting an alternative mechanism(s) eliciting the antileukemic activity in some AML cells, which may be subtype specific. This is similar to a report assessing the activity of DHA in HL-60 AML cells, which found induction of apoptosis to be ironand p38 MAPK activation-dependent but independent of ROS production [8] . Taken together, these data suggest multiple mechanisms contributing to the observed in vitro antileukemic activity of artemisinins in AML. Given the enhanced activity in MLL-and FLT3-ITDpositive AML, we evaluated the antileukemic activity using primary patient samples harboring each of these mutations.
Since multiple studies have reported that the microenvironment, including MSCs, can inhibit apoptosis and enhance the proliferation of leukemic cells through several signaling pathways, such as Mcl-1, Bad, and Akt-1 resulting in chemotherapeutic resistance [22, 23] , we performed our cell viability assays using primary patient blast samples co-cultured with MSCs. We found a tenfold increase in the IC 50 compared to AML cell lines alone indicating that primary cells are more resistant to ART treatment. These findings suggest the microenvironment may influence the in vivo activity of artemisinins in AML.
Enhanced antileukemic activity was observed with combination of ART or DHA and Ara-C administered in a simultaneous or sequential manner in both AML cell lines and primary patient blast samples. The synergistic effect of both simultaneous and sequential treatment of artemisinins in combination with Ara-C provided a rationale to pursue evaluation of in vivo efficacy of single agent and combination treatment. While single-agent ART or combination with Ara-C did not result in a prolonged survival in a MV4-11 xenograft, we did observe a decrease in leukemic infiltration with combination therapy in the initial weeks of treatment compared to vehicle-treated mice. This is similar or increasing concentrations of ART, cytarabine (Ara-C), or both at a fixed concentration ratio for 96 h, and cell viability was measured using Cell Titer Glo. To assess drug combination effect, combination index (CI) values were generated using Calcusyn. CI value >1.0, antagonistic; CI value =1.0, additive; CI value <1.0, synergistic. Data are mean ± SEM of three replicates 1 3 to a previous study that only demonstrated tumor regression and did not report any survival benefit from treatment with the antimalarial agent mefloquine in murine models of AML [9] .
Our pharmacokinetic study revealed a similar AUC after a single oral dose of ART 120 mg/kg in mice compared to the AUC in humans at oral doses administered for treatment of malaria (2-4 mg) [19, 24] . Taken the short half-life of ART and in an effort to achieve longer exposure, we proposed ART needs to be given twice or even three times daily to provide a therapeutic benefit. Therefore, we performed in vivo efficacy studies using a twice daily dosing regimen in two additional xenograft models. We found that 120 mg/kg twice daily for 5 days was the maximum tolerated dose in the NSG mouse strain; however, additional treatment at a reduced dose of 100 mg/kg twice daily for 5 days during week 2 in the ML-2 xenograft suppressed the outgrowth of leukemia and increased survival compared to mice treated with vehicle. Thus, future studies will need to optimize the dosing regimen to increase daily exposure in order to improve survival outcomes in vivo. This may be achieved through increasing the frequency of dosing to three times daily; however, the potential risk of toxicity should be considered. Due to the short plasma halflife, artemisinins are generally administered in combination with other antimalarial agents [25] and we speculate that artemisinins, as a monotherapy, will not provide longterm clinical outcomes in AML. Alternatively, given that recent studies have demonstrated a high anticancer activity of multimeric artemisinin conjugates [5, 26, 27] and artemisinin-transferrin conjugates [28] [29] [30] , implementation of a targeted delivery system may allow for more favorable Fig. 5 Antileukemic effect of artesunate in ML-2 and MOLM-13 xenograft models. Leukemic cell bone marrow infiltration was monitored by noninvasive luciferase imaging during treatment in female NSG mice engrafted with a ML-2-Luc/YFP-positive cells treated with vehicle (black), ART 120 mg/kg twice daily (BID) for 5 days during week 1 followed by ART 100 mg/kg twice daily for 5 days during week 2 (red), or ART 100 mg/kg twice daily for 10 consecutive days (blue); or b MOLM-13-Luc/YFP-positive cells treated with vehicle (black), artesunate (ART) 120 mg/kg once daily for 5 days (red), or 100 mg/kg ART 100 mg/kg twice daily for 9 consecutive days (blue). Kaplan-Meier analysis of animal survival in c the ML-2 xenograft and d MOLM-13 xenograft. Arrows indicate treatment schedule; solid arrow once daily treatment; dashed arrow twice daily treatment; BID, twice daily treatment. *P < 0.001 pharmacokinetic properties while minimizing potential side effects. However, it remains to be determined whether these synthetic derivatives will be more effective and tolerable in combination with chemotherapeutics.
In conclusion, artemisinins demonstrated activity in AML in vitro with increased selectivity against MLL-rearranged and FLT3-ITD-positive AML, which are associated with poor outcomes. Collectively, we found multiple mechanisms contributing to the in vitro activity of artemisinins. Our results suggest that the microenvironment, especially MSCs, may hinder the antileukemic activity of artemisinins and this may be overcome through combination treatment strategies with Ara-C. While our findings are consistent with artemisinins having activity in AML subtypes with poor prognosis, strategies to increase exposure of these agents, as demonstrated in the ML-2 xenograft model, or implementation of a drug formulation permitting continuous exposure (e.g., polymer or liposome), should be considered in an effort to elicit maximum antileukemic potential. In order for artemisinins to improve clinical outcomes in the treatment of AML, future efforts should focus on development of antimalarial compounds with more favorable pharmacokinetic properties and rational combinations that can overcome refractory disease or mechanisms of resistance.
